JOUNCE THERAPEUTICS INC (JNCE)       1.21  0 (0%)

1.21  0 (0%)

US4811161011 - Common Stock - After market: 1.21 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Registered users have access to more data. Please register or login for additional estimates.

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates


2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
147.9M
126.84%
62.3M
-57.88%
26.907M
-56.81%
7.65M
-71.57%
EBITDA
56.7M
306.18%
-41.7M
-173.54%
-88.229M
-111.58%
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
52.8M
268.69%
-45.1M
-185.42%
-91.056M
-101.90%
-125.815M
-38.17%
Operating Margin
35.70%-72.39%-338.41%-1,644.64%
EPS
1.63
296.39%
-1.47
-190.18%
-1.84
-25.17%
-2.43
-32.21%

All data in USD


Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates


Q3 / 22 Q4 / 22 Q1 / 23 Q2 / 23 Q3 / 23 Q4 / 23
EPS-0.65
-10.36%
-0.20
66.29%
Revenue22.848M
EBITDAN/AN/AN/AN/AN/AN/A
EBIT-33.632M
-11.58%
-7.514M
75.19%

All data in USD


EPS and Revenue Surprises


Recent Earnings VS Estimates (USD)
Period Reported Estimate Difference Surprise Q3 2022 -0.60 -0.65 0.057.85% Q2 2022 -0.65 -0.69 0.045.77% Q1 2022 -0.72 -0.59 -0.13-22.76% Q4 2021 -0.59 -0.32 -0.27-82.18% Q3 2021 -0.59 -0.45 -0.14-31.46% Q2 2021 -0.08 -0.37 0.2978.21% Q1 2021 -0.58 -0.42 -0.16-38.21% Q4 2020 0.86 0.22 0.64288.29%
Recent Revenue VS Estimates (USD)
Period Reported Estimate Difference Surprise Q3 2022 % Q2 2022 212.497K -212.497K-100.00% Q1 2022 692.141K -692.141K-100.00% Q4 2021 12.559M -12.559M-100.00% Q3 2021 6.613M -6.613M-100.00% Q2 2021 25.368M 8.34M 17.028M204.17% Q1 2021 1.5M 12.043M -10.543M-87.54% Q4 2020 62.3M 40.056M 22.244M55.53%

EPS and Revenue Revisions


Next Q (1 month)Next Q (3 month)Next Year (1 month)Next Year (3 month)
EPS52.44% 56.51% 0% 1.78%
Revenue148.89% 103.64% 0% -18.18%